Ricin is a fast-acting protein toxin classified by the Centers for Disease Control and 23 Prevention as a biothreat agent. In this report we describe five new mouse monoclonal antibodies 24 (mAbs) directed against an immunodominant region, so-called epitope cluster II, on the surface 25 of ricin's ribosome-inactivating enzymatic subunit, RTA. The five mAbs were tested alongside 26 four previously described cluster II-specific mAbs for their capacity to passively protect mice 27 against 10 x LD50 ricin challenge by injection. Only three of the mAbs (LE4, PH12 and TB12) 28 afforded protection over the seven-day study period. Neither binding affinity nor in vitro toxin-29 neutralizing activity could fully account for LE4, PH12 and TB12's potent in vivo activity 30 relative to the other six mAbs. However, epitope mapping studies by hydrogen exchange-mass 31 spectrometry (HX-MS) revealed that LE4, PH12 and TB12 shared common contact points (i.e.,
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or 154-163, or engaged with just one (but not both) of those particular secondary elements. For 168 example, CH1 and SWB1 protected residues 154-163 but not residues 63-69, while 6C4 engaged 169 with residues 63-69 but not 154-163. SyH7, PA1, and WECH1 do not interact with either 170 residues 154-163 or residues 63-69. It is tempting to speculate that simultaneous binding of an 171 antibody to residues 63-69 and 154-163 (or at least in close proximity to these residues) is a 172 determining factor in antibody potency in vivo. We will touch on this topic in the Discussion. 173 At the level of resolution afforded by HX-MS, PH12, TB12 and LE4 appeared to have 174 the same epitope (13). However, we reported that PH12 and TB12 have different profiles in 175 competition ELISAs with a panel of ~60 VHHs, suggesting that the two mAbs do have distinct 176 binding sites on RTA or different angles of approach (16). To better resolve the LE4 epitope vis 177 a vis PH12 and TB12, we subjected LE4 to similar competition ELISAs with a subset of VHHs.
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As shown in Figure 5 , LE4, PH12 and TB12 each had unique competition profiles. For example,
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PH12 and TB12 did not compete with VHH JNM-E4, whereas LE4 did. TB12 did not compete 180 with VHH JIY-D9, while PH12 and LE4 did. Finally, LE4 and PH12 did not compete with VHHs 181 JIZ-B7 and V5E1, but TB12 did. Thus, PH12, TB12 and LE4 are in fact distinct mAbs with 182 subtle differences in epitope specificity and/or different angles of approach on ricin toxin. In previous reports we delineated four neutralizing hotspots on the surface of ricin toxin's 186 enzymatic subunit, RTA, that we refer to as epitope clusters I-IV. Cluster I has been interrogated 187 in detail; it is now established that potent toxin-neutralizing activity is associated with antibodies 188 that contact residues within RTA's a-helix B (97-107) and to a much lesser degree β-strand h 189 (14, 15, (19) (20) (21) . By contrast, much less is known about cluster II. Recently, we employed HX-190 MS analysis to localize the epitopes recognized by four so-called cluster II legacy mAbs: TB12, 191 PH12, SyH7, and PA1 (13). In the current report, we have now characterized five additional 192 cluster II mAbs. The five new mAbs, LE4, CH1, SWB1, 6C4, and WECH1, were tested side-by- concentrations shown on the X-axis were mixed with ricin toxin (10 ng/ml) and applied to Vero 521 cells for 2 h. The cells were washed and incubated for ~48 h before being assessed for viability.
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Shown are representative cytotoxicity assays. Actual IC50 values are presented in Table 1 . to C-terminus as shown in Table S1 . Composite image of the four cluster II structural contact points listed in Table 1 mapped onto the 549 structure of ricin (PDB ID 2AAI) using PyMol. (B-F) Individual epitopes for indicated mAbs.
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Colors: RTA, light gray; RTB, dark gray; b-strand a-a-helix A, yellow; d-e, orange; D-E, blue; 551 F-G, green. -187,189-199,210,203,205-206 α-helices F-G
Tables

WECH1
II 2-4 14-20,22-24 α-helix A -90 185-187,189-199, 201, 203, 205-207 α-helices F-G a , actual exchange profiles and entire RTA peptide list and corresponding residues are provided in Figure 3 . 
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